NVAX Share Price

Open 1.30 Change Price %
High 1.33 1 Day -0.01 -0.77
Low 1.28 1 Week 0.05 4.03
Close 1.29 1 Month -0.22 -14.57
Volume 2585814 1 Year -3.92 -75.24
52 Week High 8.49
52 Week Low 1.16
NVAX Important Levels
Resistance 2 1.34
Resistance 1 1.32
Pivot 1.30
Support 1 1.26
Support 2 1.24
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
FTR 1.98 -1.98%
FTR 1.98 -1.98%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.10 100.00%
LOCM 0.09 50.00%
SSH 2.31 32.76%
SSH 2.31 32.76%
SSH 2.31 32.76%
LTRE 2.40 31.87%
HPJ 4.90 30.67%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
ORIG 0.23 -68.49%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Novavax, Inc. (NASDAQ: NVAX)

NVAX Technical Analysis 5
As on 28th Mar 2017 NVAX Share Price closed @ 1.29 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.69 & Strong Sell for SHORT-TERM with Stoploss of 1.39 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVAX Target for March
1st Target up-side 1.78
2nd Target up-side 1.97
3rd Target up-side 2.16
1st Target down-side 1.24
2nd Target down-side 1.05
3rd Target down-side 0.86
NVAX Other Details
Segment EQ
Market Capital 253984256.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.novavax.com
NVAX Address
NVAX
20 Firstfield Road
Gaithersburg, MD 20878
United States
Phone: 240-268-2000
NVAX Latest News
Interactive Technical Analysis Chart Novavax, Inc. ( NVAX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novavax, Inc.
NVAX Business Profile
Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.